A nucleic vaccine is to directly introduce an exogenous gene (DNA or RNA) encoding an antigen protein into an animal body cell, and synthesize the antigen protein through an expression system of a host cell to induce the host to produce an immune response to the antigen protein to achieve prevention And the purpose of treating the disease.

Market Analysis and Insights: Global Nucleic Vaccine Market
In 2020, the global Nucleic Vaccine market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% between 2021 and 2027
Global Nucleic Vaccine Scope and Market Size
The global Nucleic Vaccine market is segmented by region (country), company, by Type, and by Application. Players, stakeholders, and other participants in the global Nucleic Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), byType, and by Application for the period 2016-2027.

Segment by Type
Preventive Nucleic Vaccine
Therapeutic Nucleic Vaccine

Segment by Application
Hospital
Clinic
Others

By Company
Moderna
CureVac
Inovio
Sanofi
GSK
CNBG
Hualan Bio
Zhifei Shengwu
Liaoning Chengda
BioKangtai
CanSinoBIO
Walvax Biotechnology
Fosun Pharma

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Colombia
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE